<DOC>
	<DOC>NCT00241020</DOC>
	<brief_summary>Hepatocellular carcinoma (HCC) is one of the most common malignant disease worldwide with an increasing incidence in industrialized countries. For patients with advanced HCC no efficient treatment is currently available. The objective of this study is to assess the efficacy and safety of octreotide in patients with advanced hepatocellular carcinoma.</brief_summary>
	<brief_title>Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>&gt; 18 years HCC diagnosis : histologically or cytologically proven HCC or association of the three following criteria: cirrhosis typical measurable mass (&gt; 3cm, by 2 methods) serum alphafoetoprotein (AFP) ≥500 µg/L Cancer Liver Italian Program (CLIP) score : 0 to 3 Not eligible for specific treatment (surgery, percutaneous ablation or chemoembolization) Glycemia &gt; 2.5 g/L or hypoglycemia Extra hepatic lifethreatening disease Serum creatinin&gt; 120 µmol/L Prothrombin time &lt; 50 % Platelet count &lt; 50.000 /µL Symptomatic cholelithiasis Nonmeasurable tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>Octreotide</keyword>
</DOC>